DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO
Home/Compounds/Dihexa
Cognitive

Dihexa

Also known as: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide

Potent nootropic peptide derivative, 10 million times more potent than BDNF at promoting synaptogenesis.

C
Grade C
Animal studies only
Human studies7
PubMed citations8
Typical dose5 mg – 20 mg
Routesublingual, subcutaneous
Regulatory (US)Research only
Last verified4 days ago
TL;DR · 30-second summary
  • 10^7 times more potent than BDNF
  • Restores cognitive function in animal dementia models
  • Promotes synaptogenesis and neuroplasticity
  • Oral bioavailability demonstrated

Mechanism of action

Angiotensin IV analog that activates hepatocyte growth factor (HGF) system. Dramatically increases dendritic spine density and synaptogenesis. Crosses blood-brain barrier.

Evidence summary

7
Human studies
8
PubMed citations
0
Clinical trials
C
Evidence grade

Preclinical studies show remarkable cognitive enhancement and neuroprotection. No human trials yet. Popular in nootropic community.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Dose range
5 mg – 20 mg

Sublingual: 5-20mg daily. Very potent - start low. No established human protocols.

Administration routes
sublingualsubcutaneous

Side effects & safety

Reported side effects
Unknown - no human safety dataTheoretical cancer concern (HGF pathway)
Contraindications
  • Cancer (HGF promotes tumor growth)
  • No human safety data

Interactions

No documented drug interactions on file.

Regulatory status

United States
Not FDA approved

Not FDA approved. Research chemical only.

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/17/2026

Clinical trials

No indexed ClinicalTrials.gov studies for Dihexa. This usually means the compound isn't being studied under an IND — check the citations section for peer-reviewed research instead.

Citations

PMID 41490200Rahman OF, Lee SJ et al. · Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026)HumanPMID 38489193Wells RG, Azzam AF et al. · Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats.Journal of Huntington's disease (2024)PMID 35410439Pan T, Wang N et al. · Efficiently generate functional hepatic cells from human pluripotent stem cells by complete small-molecule strategy.Stem cell research & therapy (2022)HumanPMID 34827486Sun X, Deng Y et al. · AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway.Brain sciences (2021)HumanPMID 25649658Wright JW, Harding JW · The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease.Journal of Alzheimer's disease : JAD (2016)HumanPMID 25674052Uribe PM, Kawas LH et al. · Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure.Frontiers in cellular neuroscience (2015)HumanPMID 23055539McCoy AT, Benoist CC et al. · Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents.The Journal of pharmacology and experimental therapeutics (2013)HumanPMID 18097939Bapst JP, Froidevaux S et al. · Dimeric DOTA-alpha-melanocyte-stimulating hormone analogs: synthesis and in vivo characteristics of radiopeptides with high in vitro activity.Journal of receptor and signal transduction research (2008)Human